Chardan Capital Raises PT to $20 for Orchestra BioMed, Maintains Buy Rating

jueves, 13 de noviembre de 2025, 9:08 am ET1 min de lectura
OBIO--

Chardan Capital Raises PT to $20 for Orchestra BioMed, Maintains Buy Rating

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios